Parker Geoffrey M.
- SEC CIK
- 0001491874
In the past year, 1 open-market purchase filing worth $106.3K and 2 sale filings worth $88.5K.
Current role at each company
- PRGO PERRIGO Co plcDirectoras of Sep 15, 2026
- ALLO Allogene Therapeutics, Inc.CHIEF FINANCIAL OFFICERas of Feb 4, 2026
- BTTX Better Therapeutics, Inc.Directoras of Dec 20, 2023
- ChemoCentryx, Inc.Directoras of Oct 24, 2022
- TCDA Tricida, Inc.COO, CFO and EVPas of Mar 2, 2022
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- $106.3K
- 1 filing
- Sold
- $88.5K
- 2 filings
- Net
- +$17.8K
- Bought minus sold
- Companies
- 2
- With open-market trades
Trades
Every Form 4 that lists Parker Geoffrey M. as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
ALLO Allogene Therapeutics, Inc.
CHIEF FINANCIAL OFFICER4 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 4, 2026 (view filing) | Feb 2 | 2 days | Parker Geoffrey M.CHIEF FINANCIAL OFFICER | SSale | −24.0K | $1.76 | −$42.2K | −1.9%1.25M after | |
| Oct 23, 2025 (view filing) | Oct 21 | 2 days | Parker Geoffrey M.CHIEF FINANCIAL OFFICER | SSale | −36.7K | $1.26 | −$46.3K | −2.8%1.28M after | |
| Feb 5, 2025 (view filing) | Feb 3 | 2 days | Parker Geoffrey M.CHIEF FINANCIAL OFFICER | SSale | −4.36K | $1.73 | −$7.54K | −0.3%1.30M after | |
| Mar 6, 2024 (view filing) | Jan 30 | 36 daysLate | Parker Geoffrey M.CHIEF FINANCIAL OFFICER | PPurchase | +190 | $3.60 | +$684 | 0.0%819.6K after |
PRGO PERRIGO Co plc
Director6 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 14, 2025 (view filing) | Nov 12 | 2 days | Parker Geoffrey M.Director | PPurchase | +7.50K | $14.18 | +$106.3K | +75.9%17.4K after | |
| Aug 20, 2025 (view filing) | Aug 18 | 2 days | Parker Geoffrey M.Director | PPurchase | +4.38K | $22.97 | +$100.5K | +79.5%9.88K after | Amended |
| May 14, 2025 (view filing) | May 12 | 2 days | Parker Geoffrey M.Director | PPurchase | +3.50K | $27.10 | +$94.8K | +17.3%23.8K after | |
| Jun 14, 2023 (view filing) | Jun 13 | 1 day | Parker Geoffrey M.Director | PPurchase | +10.0K | $33.06 | +$330.6K | +63.0%25.9K after | |
| Mar 7, 2023 (view filing) | Mar 6 | 1 day | Parker Geoffrey M.Director | PPurchase | +5.00K | $38.05 | +$190.3K | +46.0%15.9K after | |
| Dec 17, 2021 (view filing) | Dec 16 | 1 day | Parker Geoffrey M.Director | PPurchase | +5.00K | $36.85 | +$184.3K | +85.0%10.9K after |
BTTX Better Therapeutics, Inc.
Director5 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 31, 2023 (view filing) | Jul 27 | 4 days | Parker Geoffrey M.Director | PPurchase | +685.0K | $0.73 | +$500.1K | +199.7%1.03M after | |
| Apr 12, 2023 (view filing) | Apr 10 | 2 days | Parker Geoffrey M.Director | PPurchase | +303.0K | $0.83 | +$251.5K | +757.6%343.0K after | |
| Jun 14, 2022 (view filing) | Jun 13 | 1 day | Parker Geoffrey M.Director | PPurchase | +25.0K | $1.45 | +$36.3K | +166.7%40.0K after | |
| Mar 31, 2022 (view filing) | Mar 29 | 2 days | Parker Geoffrey M.Director | PPurchase | +15.0K | $2.15 | +$32.3K | New position15.0K after | |
| Dec 16, 2021 (view filing) | Dec 14 | 2 days | Parker Geoffrey M.Director | PPurchase | +20.0K | $4.94 | +$98.8K | +60.0%53.3K after |